Literature DB >> 9697726

Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization.

G R Jones1, M Christodoulides, J L Brooks, A R Miller, K A Cartwright, J E Heckels.   

Abstract

Meningococcal carriage and the immune response to colonization were studied in a group of military recruits undergoing basic training. Subtyping by determination of the class 1 protein sequence clearly differentiated between strains and demonstrated the dynamics of carriage and transmission. Expression of class 1 protein by each strain remained stable during prolonged carriage by different subjects. Following colonization, a marked increase in serum bactericidal response occurred, which was specific for the subtype of the acquired strain and was associated with an increase in reactivity by Western blot to the homologous class 1 protein. Subjects colonized by multiple strains showed evidence of a specific immune response to the class 1 protein of each strain acquired. The subtype specificity of the bactericidal response to meningococci and the stability of expression of the class 1 protein have important implications for the design of vaccines for prevention of serogroup B meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697726     DOI: 10.1086/515622

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Detection of meningococcal carriage by culture and PCR of throat swabs and mouth gargles.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; John E Heckels
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

2.  Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Authors:  Kay O Johswich; Shannon E McCaw; Lea Strobel; Matthias Frosch; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

3.  Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination.

Authors:  D A Ala'Aldeen; K R Neal; K Ait-Tahar; J S Nguyen-Van-Tam; A English; T J Falla; P M Hawkey; R C Slack
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Analysis of pathogen-host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo.

Authors:  O B Harrison; B D Robertson; S N Faust; M A Jepson; R D Goldin; M Levin; R S Heyderman
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

5.  Genetic basis for biosynthesis of the (alpha 1-->4)-linked N-acetyl-D-glucosamine 1-phosphate capsule of Neisseria meningitidis serogroup X.

Authors:  Yih-Ling Tzeng; Corie Noble; David S Stephens
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

6.  Neisseria meningitidis serogroup X sequence type 767 in Turkey.

Authors:  Abdullah Kiliç; Orhan Bedir; A Celal Basustaoglu; Holly B Bratcher; Keith A Jolley; Gurkan Mert
Journal:  J Clin Microbiol       Date:  2010-08-25       Impact factor: 5.948

7.  Neisseria meningitidis lactate permease is required for nasopharyngeal colonization.

Authors:  Rachel M Exley; Linda Goodwin; Eva Mowe; Jonathan Shaw; Harry Smith; Robert C Read; Christoph M Tang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 8.  Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.

Authors:  Amy C Sherman; David S Stephens
Journal:  Expert Rev Vaccines       Date:  2020-04-29       Impact factor: 5.217

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.